I am a molecular biologist with a PhD in Tumor Immunology and a second-level Master’s in Healthcare and Pharmaceutical Administration. My background bridges translational research, clinical innovation, and healthcare system transformation. I have worked in molecular oncology, biomarker discovery, and public health, with a recent focus on digital health and medtech innovation. This multidisciplinary experience has equipped me with a strategic perspective on scientific and healthcare challenges.
Throughout my career, I have authored several peer-reviewed publications. A key study published in Neuro-Oncology (2021) identified a molecular signature linked to prolonged survival in glioblastoma patients treated with Regorafenib. I also developed a diagnostic serum microRNA signature for glioma (Journal of Neuro-Oncology, 2018) and explored circulating microRNAs as non-invasive biomarkers (Annals of Translational Medicine, 2017). My work includes studies on tumor microenvironment and immune suppression (Cell Reports, 2016), epigenetic regulation of MGMT in glioblastoma (Oncotarget, 2016), and SPARC’s role in inflammation and fibrosis (American Journal of Pathology, 2011). During my PhD, I focused on SPARC’s involvement in epithelial-mesenchymal transition (EMT) and resistance to therapy, contributing to a better understanding of cancer progression and fibrotic processes. My latest work (Applied Sciences, 2025) explores digital solutions, reflecting my focus on healthcare innovation
I am a molecular biologist with a PhD in Tumor Immunology and a second-level Master’s in Healthcare and Pharmaceutical Administration. My background bridges translational research, clinical innovation, and healthcare system transformation. I have worked in molecular oncology, biomarker discovery, and public health, with a recent focus on digital health and medtech innovation. This multidisciplinary experience has equipped me with a strategic perspective on scientific and healthcare challenges.
Throughout my career, I have authored several peer-reviewed publications. A key study published in Neuro-Oncology (2021) identified a molecular signature linked to prolonged survival in glioblastoma patients treated with Regorafenib. I also developed a diagnostic serum microRNA signature for glioma (Journal of Neuro-Oncology, 2018) and explored circulating microRNAs as non-invasive biomarkers (Annals of Translational Medicine, 2017). My work includes studies on tumor microenvironment and immune suppression (Cell Reports, 2016), epigenetic regulation of MGMT in glioblastoma (Oncotarget, 2016), and SPARC’s role in inflammation and fibrosis (American Journal of Pathology, 2011). During my PhD, I focused on SPARC’s involvement in epithelial-mesenchymal transition (EMT) and resistance to therapy, contributing to a better understanding of cancer progression and fibrotic processes. My latest work (Applied Sciences, 2025) explores digital solutions, reflecting my focus on healthcare innovation